Huangqi injection (HQI), derived from Astragalus membranaceus, is investigated as a supplementary treatment for hypertensive nephropathy alongside traditional antihypertensive drugs.
A systematic review of 15 studies with 1,483 participants shows that HQI combined with antihypertensive medication significantly improves key health indicators like protein levels in urine, blood pressure, and kidney function compared to antihypertensive drugs alone.
The findings suggest that using a moderate dose of HQI enhances treatment effects for hypertensive nephropathy, making it a valuable addition to standard antihypertensive therapy.